Cell-Specific Precision Targeting Oligo-drugs are complexed with Schizophyllan (SPG, a beta glucan) and protected from degradative enzymes while being delivered to immature dendritic cells (iDC) or to macrophages via Dectin-1, a natural receptor for glucans. By specifically delivering the oligo to the target cells, a low dose can be used making reduced toxicity possible while implementing sequence specific efficacy.

Flexible Immunomodulatory Platform By loading different therapeutic payloads onto its cell-specific delivery platform and targeting upstream biology, NapaJen has made both “precision-targeted immuno-tolerance” as well as “controlled immuno-stimulatory” treatment possible in preclinical models while avoiding normal / healthy immune cells.

alignright